Immuto Scientific is opening new frontiers in the fight against cancer by developing precision biotherapeutics that target highly cancer-specific surface protein conformations. Their ultimate goal is to make cancer curable.
Immuto Scientific was one of the companies supported by the National Institutes of Health (NIH) SEED program that was chosen to present on the NIH Innovation Zone Stage at the 2024 BIO International Convention.
Bio.News interviewed Immuto Scientific CEO Faraz A. Choudhury, Ph.D, about the ongoing work of the Wisconsin-based biotech firm.
Read the interview here: https://bio.news/bio-convention/nih-innovation-zone-2024-immuto-scientific-identifies-new-cancer-targets/